Mayne Pharma reports unaudited 3Q FY26 results
Released
Released
Announcement PDF
ASX Announcement
MAYNE PHARMA REPORTS UNAUDITED 3Q FY26 RESULTS
Highlights1
• Successful launch of DistributeRx in March with strong initial prescription demand significantly ahead of internal
forecasts (+72%) and pre-launch volumes for February (+73%) and the pcp (+92%)
• Strong growth in Women’s Health menopause portfolio with total prescriptions (TRx)2
for BIJUVA®
up 30% versus
the pcp and in contraception NEXTSTELLIS®
demand cycles up 12% versus the pcp
• No material earnings impact from US tariff proclamation on 7 April
• Reported revenue of $85.2 million (+1% pcp) with gross margin of 63% (+400 bps v pcp), reflecting disciplined
pricing, mix and channel execution
• Underlying EBITDA of -$1.4 million (+57% pcp) with total direct segment contribution3
of $17.9 million (+11%
pcp), underpinned by Dermatology (+43% pcp)
• Adjusted operating cash flow from continuing operations4
of $28.3million (+90% pcp)
• Net cash flow of $19.3 million; cash and marketable securities of $86.7 million at 31 March 2026 (+29% from 31
December 2025)
29 April 2026, Adelaide, Australia: Mayne Pharma Group Limited (Mayne Pharma or the Company) (ASX:
MYX), today announces an unaudited financial and operating update for the three months ended 31 March
2026 (3Q FY26).
Group Financial Overview
$ million
3Q FY26 3Q FY25
Change vs
3Q FY25
% Change vs
3Q FY25
Revenue $85.2m $84.3m +$0.9m +1%
Gross Profit $53.4m $49.6m +$3.8m +8%
Direct Contribution $17.9m $16.1m +$1.8m +11%
Reported EBITDA ($4.5m) ($5.0m) +$0.5m +10%
Underlying EBITDA5
($1.4m) ($3.3m) +$1.9m +57%
Net Loss After Tax ($21.0m) ($22.5m) +$1.5m +7%
Adjusted cash flow from continuing operations $28.3m $14.9m +$13.4m +90%
Mayne Pharma’s CEO, Mr Aaron Gray said “The launch of DistributeRx in March translated our
disintermediation strategy into action and is already delivering prescription volumes significantly ahead of
plan. Combined with standout prescription growth from BIJUVA® and NEXTSTELLIS®, a meaningful regulatory
tailwind from the FDA's update to hormone therapy labelling and strong cash generation across the business,
we enter 4Q FY26 with real commercial momentum.”
1
All amounts are expressed in Australian Dollar Terms (A$/AUD) unless otherwise indicated and all figures are unaudited. Amounts include FX effects.
2
TRx data includes IQVIA data, plus prescription volume through non-reporting pharmacies (including Mayne Pharma’s own distribution channel).
3
Direct contribution calculated as gross margin less direct opex.
4
Total net operating cashflow excluding outflows for discontinued operations and legal expenses (Scheme). Earnout payments recognised as financing
cash outflows.
5
Underlying EBITDA excludes earn-out reassessments, litigation and restructuring charges, derivative fair value adjustments, other.
ASX Announcement
Page 2
Financial and Operational Summary
The 3Q of each financial year encompasses the annual reset of US patient insurance deductibles and co-
pay cards, which increases the Company's gross to net (GTN) expense at a time when patient out-of-pocket
costs are at their highest, creating a dual headwind of softer demand and elevated GTN that typically
moderates as patients progress through their deductible year (1 January to 31 December).
Mayne Pharma generated $28.3 million in adjusted operating cash flows up 90% versus the prior
corresponding period (pcp). The Company notes the main driver of the strong operating cash flow relates
to the timing effect of certain GTN cash payments which are expected to be made in 4Q FY26. Cash flows
from discontinued operations continued to decline to $1.4 million (down 30% on the pcp). A total of $19.3
million in net cash flow drove a 29% increase in cash and marketable securities of $86.7 million from 31
December 2025.
Revenues were up 1% to $85.2 million versus the pcp, with gross margins of 63% driven by price discipline,
mix effects and channel execution. Total direct contribution was up 11% versus the pcp, reflecting top-line
growth and operating cost discipline and underlying EBITDA was -$1.4 million, up 57 % versus the pcp. The
quarterly result reflects the underlying earnings quality of the business and continued focus on working
capital management. This strong cash generation provides the Company with the financial flexibility to
reinvest in its growth priorities and pursue capital-efficient business development opportunities.
Women’s Health
During the March quarter, Mayne Pharma’s Women’s Health business continued to build momentum, with
BIJUVA® and NEXTSTELLIS® leading portfolio growth, supported by refreshed campaigns, optimised
healthcare provider (HCP) engagement and a stronger commercial focus across key territories. In
menopause, BIJUVA® became one of only six products to have its boxed warning updated by the FDA in
February 2026, removing language related to cardiovascular risk, breast cancer and probable dementia —
a development the Company believes will meaningfully support HCP confidence and prescribing. The
increased demand for BIJUVA® resulted in a temporary supply disruption in late April. The Company
expects supply to resume within the coming weeks.
The Women’s Health growth strategy is focused on increasing share of voice, improving field force
effectiveness and converting demand more efficiently. Given the growth in the menopause market, Mayne
Pharma will prioritise investment into this segment to grow sales particularly for women earlier in their
treatment journey.
Key 3Q FY26 financial highlights include:
• Revenue of US$26.4 million (+7% versus pcp)
o NEXTSTELLIS® demand cycles6
up 12% and net sales of US$11.7 million (+19%);
o ANNOVERA® total prescriptions (TRx) down 2% and net sales of US$5.7 million (0%);
o IMVEXXY® TRx up 4% and net sales of US$4.6 million (-12%); and
o BIJUVA® TRx up 30% and net sales of US$3.7 million (+26%)
6
Calculated as IQVIA reported TRx (converted to units/cycles) plus non-reporting pharmacies (including Mayne Pharma’s own distribution
channel). TRx converted to units by taking number of pills in the TRx divided by 28 (number of NEXTSTELLIS® pills included in 1 month of
therapy). NEXTSTELLIS® prescriptions can be prescribed in 1-month and 3-month increments. On average 1 TRx equals 2.0 units/cycles.
ASX Announcement
Page 3
• Gross profit of US$21.1 million (+8% versus pcp) and gross margin of 80% (flat versus pcp)
• Direct contribution of US$7.1 million (+6% versus pcp)
Dermatology / DistributeRx
During the quarter, Mayne Pharma focussed on the launch of DistributeRx7
a major commercial milestone
for the Company. DistributeRx is a healthcare solutions business that partners with manufacturers to
streamlinetheprescription distribution processand expand patient accesstomedications. Theoperational
arms of the business include customer-facing, manufacturer and pharmacy services. Mayne Pharma’s
dermatology sales force has been fully onboarded into DistributeRx, with a new strategic focus on selling
the advantages of DistributeRx for manufacturers, prescribers and their patients of this healthcare
ecosystem, relative to individual portfolio products.
Since launch, DistributeRx has significantly exceeded internal prescription volume (Rx) forecasts by 72%,
despite field force representation (i.e. reps) of approximately 70% of the targeted headcount at the end of
3Q FY26. Total Rx received by DistributeRx for March was approximately 6,400 representing 73% growth on
pre-launch dermatology prescription volumes received by DistributeRx in the prior month and 92% growth
on the pcp. Since launch, DistributeRx has added approximately 1,600 new prescribers. For existing
prescribers, Rx increased over 80% relative to their previous pre-launch monthly average. There exists a
significant opportunity for DistributeRx to grow territories, new prescribers and repeat Rx moving forward.
Presently, DistributeRxoffersa dermatologyportfolio consisting of31MaynePharma productsand 178 non-
Mayne Pharma dermatology products. The DistributeRx team expects to attend six industry conferences in
April to drive awareness and education.
Within the Mayne Pharma Dermatology portfolio, the Company saw strong Rx growth in generic
ACCUTANE®
with market share growth8
from 51% in the pcp to 61% versus the competitive set in 3Q FY26,
driven by a strategic digital health partnership specialising in dermatology products. RHOFADE®
maintained its prescription market share and volumes consistently throughout 3Q, while TWYNEO®
achieved better-than-expected commercial formulary coverage, with favourable prior-authorisation
outcomes thereby accelerating patient access. AG ORACEA® market share of 47% reflects ongoing generic
competition in the category.
Key 3Q FY26 financial highlights include:
• Revenue of US$20.5 million (+1% versus pcp)
• Gross profit of US$12.8 million (+34% versus pcp) and gross margin of 63% (+16% versus pcp)
• Direct contribution of US$4.7 million (+55% versus pcp)
International
The International segment continued to build commercial momentum during 3Q FY26, underpinned by
strong sales growth associated with NEXTSTELLIS®
following PBS approval in late September 2025 and
KADIAN®
in Canada following an expanded distribution agreement. Monthly NEXTSTELLIS®
prescriptions
in Australia haveincreased byapproximately 160%in 3Q FY26 versus1Q FY26 (thequarterimmediately prior
to PBS approval). Mayne Pharma continues to focus on patient and prescriber awareness to grow
NEXTSTELLIS®
in Australia. The Company continues to explore new global partnerships for product
7
See ASX announcement dated 10 March 2026
8
Market share is based on current NRx (new prescription) volume from IQVIA measured against our defined set of competitors per brand.
ASX Announcement
Page 4
manufacturing following the completion of the $18 million upgrade of the Salisbury facility, with a number
of out-licensing discussions within Asian territories under development. In addition, the Company will be
participating in a number of major conferences in Japan, China and Korea in April.
Key 3Q FY26 financial highlights include:
• Revenue of $17.7 million (+19% versus pcp)
• Gross profit of $4.6 million (+4% versus pcp) and gross margin of 26% (-4% versus pcp)
• Direct contribution of $1.0 million (-6% versus pcp)
Outlook
Mayne Pharma's strategic priorities are focused on driving sustainable growth across its Women's Health
and Dermatology segments through dedicated commercial investment, refreshed marketing, and the
continued build-out of the DistributeRx ecosystem, while actively unlocking value from international
investments including the NEXTSTELLIS®
PBS listing and expanded supply agreements. The Company
continues to examine capital allocation strategies, which may include an on-market share buy-back while
pursuing synergistic and capital-efficient business development opportunities.
For further information contact:
Dr Tom Duthy
Investor Relations
+61 402 493 727
ir@maynepharma.com
Authorised for release to the ASX by the Board Chair.
Email Alerts
To register for an email alert service to receive Mayne Pharma announcements released to the Australian
Securities Exchange (ASX) please visit https://www.maynepharma.com/investor-relations/email-alerts/
Follow us on LinkedIn
About Mayne Pharma
Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel
pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma is a leader
in dermatology and women’s health in the United States and also provides contract development and
manufacturing services to clients worldwide. Mayne Pharma has a 40-year track record of innovation and
success in developing new oral drug delivery systems. These technologies have been successfully
commercialised in numerous products that continue to be marketed around the world. To learn more
about Mayne Pharma, please visit maynepharma.com.
ACCUTANE®, ANNOVERA®, BIJUVA®, IMVEXXY®, KADIAN®, NEXTSTELLIS®, ORACEA® and TWYNEO® are
trademarks of third parties.
ASX Announcement
Page 5
Important information
This announcement contains forward-looking statements that involve subjective judgement and analysis and
are subject to significant uncertainties, risks and contingencies, many of which are outside the control of, and
are unknown to the Company. These forward-looking statements use words such as ‘potential’, ‘expect’,
‘anticipate’, ‘intend’, ‘plan’, ‘target’ and ‘may’, and other words of similar meaning. No representation,
warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by
any person (including the Company). Actual future events may vary materially from the forward-looking
statements and the assumptions on which the forward-looking statements are based. Given these
uncertainties, readers are cautioned not to place unduereliance on such forward-looking statements. Subject
to the Company’s continuous disclosure obligations at law and under the listing rules of the Australian
Securities Exchange, the Company disclaims any obligation to update or revise any forward-looking
statements. The factors that may affect the Company’s future performance include, among others: changes in
economic conditions; changes in the legal and regulatory regimes in which the Company operates; litigation
or government investigations; decisions by regulatory authorities including approval of our products as well
as their decisions on label claims; competitive developments affecting our products; changes in behaviour of
major customers, suppliers and competitors; interruptions to manufacturing or distribution; acquisitions and
divestitures; the success of research and development activities and research collaborations and the
Company’s ability to protect its intellectual property.
Share your feedback
Discover